A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer (NCT06562543)
A Single Arm Phase 4 Trial to Evaluate the Safety and Efficacy of Oral Fruquintinib in the Treatment of Refractory Metastatic Colorectal Cancer in Patients From Minority Populations Underrepresented in Prior Fruquintinib Studies
🩺 Plain-English Summary (8th-Grade Level)
High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with refractory metastatic colorectal cancer (mCRC) have a bigger risk of higher blood pressure after treatment with fruquintinib. The main aim of this study is to learn how often adults of a minority group experience hypertension after they have been treated with fruquintinib for refractory mCRC. Other aims are to learn how safe fruquintinib is and how well it is tolerated by participants. Participants will receive fruquintinib in 4-week treatment cycles until their condition worsens, they do no longer tolerate the treatment or stop the treatment for other reasons. After the last treatment, participants will be checked upon every 3 months until study completion.
Who can join: Review the eligibility criteria below.
Location: Central Alabama Research — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (45 Sites)
Showing the first 25 of 45 sites.
- Central Alabama Research — Birmingham, Alabama
- University of Alabama at Birmingham — Birmingham, Alabama
- Ironwood Cancer and Research Centers — Chandler, Arizona
- University of Arizona — Tucson, Arizona
- University of California San Diego — La Jolla, California
- University of Southern California — Los Angeles, California
- PIH Health Whittier Hospital — Whittier, California
- Christiana Care Health Services — Newark, Delaware
- University of Florida — Gainesville, Florida
- University of Miami — Miami, Florida
- Baptist Health - Miami Cancer Institute — Miami, Florida
- Emory University — Atlanta, Georgia
- Hope and Healing Cancer Services — Hinsdale, Illinois
- Indiana University — Indianapolis, Indiana
- Our Lady of the Lake Physician Group - LSU Health Baton Rouge Oncology — Baton Rouge, Louisiana
- Willis Knighton Cancer Center — Shreveport, Louisiana
- Mercy Medical Center — Baltimore, Maryland
- Boston Medical Center — Boston, Massachusetts
- Hattiesburg Clinic — Hattiesburg, Mississippi
- Saint Luke's Cancer Institute — Kansas City, Missouri
- Midwest Oncology Associates - Kansas City — Kansas City, Missouri
- SSM Health St. Louis DePaul Hospital — St Louis, Missouri
- Washington University School of Medicine — St Louis, Missouri
- Capital Health Medical Center - Hopewell — Pennington, New Jersey
- Columbia University — New York, New York
📞 Contact the Study Coordinator
Phone: (877) 825-3327
Email: medinfoUS@takeda.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Colorectal Cancer
- Impact of Colorectal Cancer and Nutrition Education Program Among Minority Patients With Type 2 Diabetes — Los Angeles, California
- A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors — Duarte, California
- Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD) — Houston, Texas
- Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver — Basking Ridge, New Jersey
- The PRIME-CRC Trial to Promote CRC Screening in Rural Communities — Bastrop, Louisiana
- Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer — Concord, California
Explore by condition: All Colorectal Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.